Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors Part 5: apoptosis and cell cycle

References

• Newton HB. Primary brain tumors: review of etiology, diagnosis, and treatment. Am. Fam. Phys. 49, 787–797 (1994).
   PubMed Web of Science ®Google Scholar
• Davis FG, McCarthy BJ. Current epidemiological trends and surveillance issues in brain tumors. Expert Rev. Anticancer Ther. 1, 395–401 (2001).
   PubMedGoogle Scholar
• Newton HB. Neurological complications of systemic cancer. Am. Fam. Phys. 59, 878–886 (1999).
   PubMed Web of Science ®Google Scholar
• Wen PY, Loeffler JS. Management of brain metastases. Oncology 13, 941–961 (1999).
   PubMed Web of Science ®Google Scholar
• Newton HB, Turowski RC, Stroup TJ, McCoy LK. Clinical presentation, diagnosis, and pharmacotherapy of patients with primary brain tumors. Ann. Pharmacother. 33, 816–832 (1999).
   PubMed Web of Science ®Google Scholar
• Fine HA, Dear KBG, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71, 2585–2597 (1993).
   PubMed Web of Science ®Google Scholar
• Newton HB. Chemotherapy for the treatment of metastatic brain tumors. Expert Rev. Anticancer Ther. 2, 495–506 (2002).
   PubMedGoogle Scholar
• Chung RY, Seizinger BR. Tumor suppressor genes and cancer of the human nervous system. Cancer Invest. 9, 429–438 (1991).
   PubMed Web of Science ®Google Scholar
• von Deimling A, Louis DN, Wiestler OD. Molecular pathways in the formation of gliomas. Glia 15, 328–338 (1995).
   PubMed Web of Science ®Google Scholar
• Shapiro JR, Coons SW. Genetics of adult malignant gliomas. BNI Q 14, 27–42 (1998).
   Google Scholar
• Maher EA, Furnari FB, Bachoo RM et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 15, 1311–1333 (2001).
   PubMed Web of Science ®Google Scholar
• Newton HB. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: Growth factor and Ras signaling pathways. Expert Rev. Anticancer Ther. 3, 89–108 (2003).
   Google Scholar
• Newton HB. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Rev. Anticancer Ther. 4, 105–128 (2004).
   PubMedGoogle Scholar
• Newton HB. Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 3: brain tumor invasiveness. Expert Rev. Anticancer Ther. 4(5), 803–821 (2004)
   PubMedGoogle Scholar
• Newton HB. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 4: p53 signaling pathways. Expert Rev. Anticancer Ther. 5(1), 177–191 (2004)
   Web of Science ®Google Scholar
• Montenarh M. Biochemical, immunological, and functional aspects of the growth suppressor/oncoprotein p53. Crit. Rev. Oncogenesis 3, 233–256 (1992).
   PubMedGoogle Scholar
• Lee JM, Bernstein A. Apoptosis, cancer and the p53 tumor suppressor gene. Cancer Metast. Rev. 14, 149–161 (1995).
   PubMed Web of Science ®Google Scholar
• Sionov RV, Haupt Y. The cellular response to p53: the decision between life and death. Oncogene 18, 6145–6157 (1999).
   PubMed Web of Science ®Google Scholar
• Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26, 239–257 (1972).
   PubMed Web of Science ®Google Scholar
• Stewart BW. Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators. J. Natl Cancer Inst. 86, 1286–1296 (1994).
   PubMed Web of Science ®Google Scholar
• Kerr JFR, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 73, 2013–2026 (1994).
   PubMed Web of Science ®Google Scholar
• Hengartner MO. The biochemistry of apoptosis. Nature 407, 770–776 (2000).
   PubMed Web of Science ®Google Scholar
• Wyllie AH. Apoptosis: cell death in tissue regulation. J. Pathol. 153, 313–316 (1987).
   PubMed Web of Science ®Google Scholar
• Ellis RE, Yuan JY, Horvitz HR. Mechanisms and functions of cell death. Ann. Rev. Cell Biol. 7, 663–698 (1991).
   PubMed Web of Science ®Google Scholar
• Goldstein P, Ojcius DM, Young JD. Cell death mechanisms and the immune system. Immunol. Rev. 121, 29–65 (1991).
   PubMed Web of Science ®Google Scholar
• Reed JC. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 17, 2941–2953 (1999).
   PubMed Web of Science ®Google Scholar
• Friedlandler RM. Apoptosis and caspases in neurodegenerative diseases. N. Engl. J. Med. 348, 1365–1375 (2003).
   PubMed Web of Science ®Google Scholar
• Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Ann. Rev. Biochem. 68, 383–424 (1999).
   PubMed Web of Science ®Google Scholar
• Nicholson DW. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ. 6, 1028–1042 (1999).
   PubMed Web of Science ®Google Scholar
• Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54, 4855–4878 (1994).
   PubMed Web of Science ®Google Scholar
• Ozbun MA, Butel JS. Tumor suppressor p53 mutations and breast cancer: a critical analysis. Adv. Cancer Res. 66, 71–141 (1995).
   PubMed Web of Science ®Google Scholar
• Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl Cancer Inst. 88, 1442–1455 (1996).
   PubMed Web of Science ®Google Scholar
• Ozbun MA, Butel JS. p53 tumor suppressor gene: structure and function. In: Encyclopedia of Cancer. Volume II. Bertino JR (Ed.), Academic Press, CA, USA 1240–1257 (1997).
   Google Scholar
• Malkin D. The role of p53 in human cancer. J. Neuro-oncol. 51, 231–243 (2001).
   PubMed Web of Science ®Google Scholar
• Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 60, 6788–6793 (2000).
   PubMed Web of Science ®Google Scholar
• Ashcroft M, Vousden KH. p53 tumor suppressor protein. In: Tumor Suppressor Genes in Human Cancer. Fisher DE (Ed.), Humana Press Inc., NJ, USA 7, 159–181 (2001).
   Google Scholar
• El-Deiry WS. Regulation of p53 downstream genes. Semin. Cancer Biol. 8, 345–357 (1998).
   PubMed Web of Science ®Google Scholar
• Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80, 293–299 (1995).
   PubMed Web of Science ®Google Scholar
• Korsmeyer SJ. Bcl-2 gene family and the regulation of programmed cell death. Cancer Res. 59, 1693S–1700S (1999).
   PubMed Web of Science ®Google Scholar
• Antonsson B, Martinou JC. The Bcl-2 protein family. Exp. Cell Res. 256, 50–57 (2000).
   PubMed Web of Science ®Google Scholar
• Gross A, McDonnell JM, Korsmeyer SJ. Bcl-2 family members and the mitochondria in apoptosis. Genes Dev. 13, 1899–1911 (1999).
   PubMed Web of Science ®Google Scholar
• Loeffler M, Kroemer G. The mitochondrion in cell death control: certainties and incognita. Exp. Cell Res. 256, 19–26 (2000).
   PubMed Web of Science ®Google Scholar
• Cain K, Bratton SB, Langlais C et al. Apaf-1 oligomerizes into biologically active approximately 700-kDa and inactive approximately 1.4-MDa apoptosome complexes. J. Biol. Chem. 275, 6067–6070 (2000).
   PubMed Web of Science ®Google Scholar
• LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17, 3247–3259 (1998).
   PubMed Web of Science ®Google Scholar
• Li F, Ambrosini G, Chu EY et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396, 580–584 (1998).
   PubMed Web of Science ®Google Scholar
• Conway EM, Pollefeyt S, Cornelissen J et al. Three differentially expressed survivin cDNA variants encode proteins with distinct anti-apoptotic functions. Blood 95, 1435–1442 (2000).
   PubMed Web of Science ®Google Scholar
• Nagata S. Apoptosis by death factor. Cell 88, 355–365 (1997).
   PubMed Web of Science ®Google Scholar
• Ashkanazi A, Dixit VM. Death receptors: signaling and modulation. Science 281, 1305–1308 (1998).
   PubMed Web of Science ®Google Scholar
• Goldstein P. Cell death: TRAIL and its receptors. Curr. Biol. 7, R750–R753 (1997).
   Google Scholar
• Irmler M, Thome M, Hahne M et al. Inhibition of death receptor signals by cellular FLIP. Nature 388, 190–195 (1997).
   PubMed Web of Science ®Google Scholar
• Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391, 43–50 (1998).
   PubMed Web of Science ®Google Scholar
• Buendia B, Santa-Maria A, Courvalin JC. Caspase-dependent proteolysis of integral and peripheral proteins of nuclear membranes and nuclear pore complex proteins during apoptosis. J. Cell Sci. 112, 1743–1753 (1999).
   PubMed Web of Science ®Google Scholar
• Kothakota S, Azuma T, Reinhard C et al. Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science 278, 294–298 (1997).
   PubMed Web of Science ®Google Scholar
• Rudel T, Bokoch GM. Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation of PAK2. Science 276, 1571–1574 (1997).
   PubMed Web of Science ®Google Scholar
• Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957–967 (1993).
   PubMed Web of Science ®Google Scholar
• Martin DS, Stolfi RL, Colofiore JR. Perspective: the chemotherapeutic relevance of apoptosis and a proposed biochemical cascade for chemotherapeutically induced apoptosis. Cancer Invest. 15, 372–381 (1997).
   PubMed Web of Science ®Google Scholar
• Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 59, 1391–1399 (1999).
   PubMed Web of Science ®Google Scholar
• Chou D, Miyashita T, Mohrenweiser HW et al. The Bax gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas. Cancer Genet. Cytogenet. 88, 136–140 (1996).
   PubMedGoogle Scholar
• Joy A, Panicker S, Shapiro JR. Altered nuclear localization of bax protein in BCNU-resistant glioma cells. J. Neuro-oncol. 49, 117–129 (2000).
   PubMed Web of Science ®Google Scholar
• Vogelbaum MA, Tong JX, Perugu R, Gutmann DH, Rich KM. Overexpression of Bax in human glioma cell lines. J. Neurosurg. 91, 483–489 (1999).
   PubMed Web of Science ®Google Scholar
• Nakasu S, Nakasu Y, Nioka H, Nakajima M, Handa J. Bcl-2 protein expression in tumors of the central nervous system. Acta Neuropathol. 88, 520–526 (1994).
   PubMed Web of Science ®Google Scholar
• Schiffer D, Cavalla P, Migheli A, Giordana MT, Chiado-Piat L. Bcl-2 distribution in neuroepithelial tumors: an immunohistochemical study. J. Neuro-oncol. 27, 101–109 (1996).
   PubMed Web of Science ®Google Scholar
• Newcomb EW, Bhalla SK, Parrish CL, Hayes RL, Cohen H, Miller DC. Bcl-2 protein expression in astrocytomas in relation to patient survival and p53 gene status. Acta Neuropathol. 94, 369–375 (1997).
   PubMed Web of Science ®Google Scholar
• Strik H, Deininger M, Streffer J et al. Bcl-2 family protein expression in initial and recurrent glioblastomas: modulation by chemoradiotherapy. J. Neurol. Neurosurg. Psych. 67, 763–768 (1999).
   PubMed Web of Science ®Google Scholar
• Korshunov A, Golanov A, Sycheva R, Pronin I. Prognostic value of tumour associated antigen immunoreactivity and apoptosis in cerebral glioblastomas: an analysis of 168 cases. J. Clin. Pathol. 52, 574–580 (1999).
   PubMed Web of Science ®Google Scholar
• Kraus J, Wenghoefer M, Glesmann N et al. TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme. J. Neuro-oncol. 52, 263–272 (2001).
   PubMed Web of Science ®Google Scholar
• McDonald FE, Ironside JW, Gregor A et al. The prognostic influence of Bcl-2 in malignant glioma. Br. J. Cancer 86, 1899–1904 (2002).
   PubMed Web of Science ®Google Scholar
• Strege RJ, Godt C, Stark AM, Hugo HH, Mehdorn HM. Protein expression of Fas, Fas ligand, Bcl-2 and TGFβ2 and correlation with survival in initial and recurrent human gliomas. J. Neuro-oncol. 67, 29–39 (2004).
   PubMed Web of Science ®Google Scholar
• Fels C, Schäfer C, Hüppe B et al. Bcl-2 expression in higher-grade human glioma: a clinical and experimental study. J. Neuro-oncol. 48, 207–216 (2000).
   PubMed Web of Science ®Google Scholar
• Frankel B, Longo SL, Ryken TC. Human astrocytomas co-expressing Fas and Fas ligand also produce TGFβ2 and Bcl-2. J. Neuro-oncol. 44, 205–212 (1999).
   PubMed Web of Science ®Google Scholar
• Tachibana O, Nakazawa H, Lampe J, Watanabe K, Kleihues P, Ohgaki H. Expression of Fas/APO-1 during the progression of astrocytomas. Cancer Res. 55, 5528–5530 (1995).
   PubMed Web of Science ®Google Scholar
• Husain N, Chiocca EA, Rainov N, Louis DN, Zervas NT. Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines. Acta Neuropathol. 95, 287–290 (1998).
   PubMed Web of Science ®Google Scholar
• Gratas C, Tohma Y, Van Meir EG et al. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol. 7, 863–869 (1997).
   PubMed Web of Science ®Google Scholar
• Frankel B, Longo SL, Leach C, Canute GW, Ryken TC. Apoptosis and survival in high-grade astrocytomas as related to tumor Fas (APO-1/CE95) expression. J. Neuro-oncol. 59, 27–34 (2002).
   PubMed Web of Science ®Google Scholar
• Rieger J, Naumann U, Glaser T, Ashkenazi A, Weller M. APO2 ligand: a novel lethal weapon against malignant glioma? FEBS Lett. 427, 124–128 (1998).
   PubMed Web of Science ®Google Scholar
• Frank S, Khler U, Schackert G, Schackert HK. Expression of TRAIL and its receptors in human brain tumors. Biochem. Biophys. Res. Comm. 257, 454–459 (1999).
   PubMed Web of Science ®Google Scholar
• Nagane M, Pan G, Weddle JJ, Dixit VM, Cavanee WK, Huang HJS. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res. 60, 847–853 (2000).
   PubMed Web of Science ®Google Scholar
• Hao C, Beguinot F, Condorelli G et al. Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apoptosis in human malignant glioma cells. Cancer Res. 61, 1162–1170 (2001).
   PubMed Web of Science ®Google Scholar
• Grotzer MA, Eggert A, Zuzak TJ et al. Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene 19, 4604–4610 (2000).
   PubMed Web of Science ®Google Scholar
• Zuzak TJ, Steinhoff DF, Sutton LN, Phillips PC, Eggert A, Grotzer MA. Loss of caspase-8 gene expression is common in childhood primitive neuroectodermal brain tumor/medulloblastoma. Eur. J. Cancer 38, 92–98 (2002).
   PubMed Web of Science ®Google Scholar
• Pingoud-Meier C, Lang D, Janss AJ et al. Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma. Clin. Cancer Res. 9, 6401–6409 (2003).
   PubMed Web of Science ®Google Scholar
• Fulda S, Debatin KM. IFN-γ sensitizes for apoptosis by upregulating caspase-8 expression through the STAT1 pathway. Oncogene 21, 2295–2308 (2002).
   PubMed Web of Science ®Google Scholar
• Chakravati A, Noll E, Black PM et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J. Clin. Oncol. 20, 1063–1068 (2002).
   PubMed Web of Science ®Google Scholar
• Sasaki T, Lopes MB, Hankins GR, Helm GA. Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system. Acta Neuropathol. 104, 105–109 (2002).
   PubMed Web of Science ®Google Scholar
• Kajiwara Y, Yamasaki F, Hama S et al. Expression of survivin in astrocytic tumors. Correlation with malignant grade and prognosis. Cancer 97, 1077–1083 (2003).
   PubMed Web of Science ®Google Scholar
• Yamada Y, Kuroiwa T, Nakagawa T et al. Transcriptional expression of survivin and its splice variants in brain tumors. J. Neuorsurg. 99, 738–745 (2003).
   PubMed Web of Science ®Google Scholar
• Kleinshchmidt-DeMasters BK, Heinz D, McCarthy PJ et al. Survivin in glioblastomas. Protein messenger RNA expression and comparison with telomerase levels. Arch. Pathol. Lab. Med. 127, 826–833 (2003).
   PubMed Web of Science ®Google Scholar
• Velculescu VE, Madden SL, Zhang L et al. Analysis of human transcriptomes. Nature Genet. 23, 387–388 (1999).
   PubMed Web of Science ®Google Scholar
• Altura RA, Olshefski RS, Jiang Y, Boue DR. Nuclear expression of survivin in paediatric ependymomas and choroid plexus tumours correlates with morphologic tumour grade. Br. J. Cancer 89, 1743–1749 (2003).
   PubMed Web of Science ®Google Scholar
• Foster BA, Coffey HA, Morin MJ, Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science 286, 2507–2510 (1999).
   PubMed Web of Science ®Google Scholar
• Hupp TR, Lane DP, Ball KL. Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochem. J. 352, 1–17 (2000).
   PubMed Web of Science ®Google Scholar
• Lane DP, Lain S. Therapeutic exploitation of the p53 pathway. Trends Mol. Med. 8, S38–S42 (2002).
   Web of Science ®Google Scholar
• Sellers WR, Fisher DE. Apoptosis and cancer drug targeting. J. Clin. Invest. 104, 1655–1661 (1999).
   PubMed Web of Science ®Google Scholar
• Stenner-Liewen F, Reed JC. Apoptosis and cancer: basic mechanisms and therapeutic opportunities in the postgenomic era. Cancer Res. 63, 263–268 (2003).
   Google Scholar
• Nicholson DW. From bench to clinic with apoptosis-based therapeutic agents. Nature 407, 810–816 (2000).
   PubMed Web of Science ®Google Scholar
• Sun SY, Hail N, Lotan R. Apoptosis as a novel target for cancer chemoprevention. J. Natl Cancer Inst. 96, 662–672 (2004).
   PubMed Web of Science ®Google Scholar
• Reed JC, Gewirtz AM, Sternberg CN, Chitambar CR. Direct targeting of apoptosis in cancer therapy. Clin. Adv. Hematol. Oncol. 1, 3–1 (2003).
   Google Scholar
• Jansen B, Schlagbauer-Wadl H, Brown BD et al. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nature Med. 4, 232–234 (1998).
   PubMed Web of Science ®Google Scholar
• Schlagbauer-Wadl H, Klosner G, Heere-Ress E et al. Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice. J. Invest. Dermatol. 114, 725–730 (2000).
   PubMed Web of Science ®Google Scholar
• Waters JS, Webb A, Cunningham D et al. Phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin’s lymphoma. J. Clin. Oncol. 18, 1812–1823 (2000).
   PubMed Web of Science ®Google Scholar
• Zangemeister-Wittke U, Leech SH, Olie RA et al. A novel bispecific antisense oligonucleotide inhibiting both Bcl-2 and Bcl-xL expression efficiently induces apoptosis in tumor cells. Clin. Cancer Res. 6, 2547–2555 (2000).
   PubMed Web of Science ®Google Scholar
• Waxman DJ, Schwartz PS. Harnessing apoptosis for improved anticancer gene therapy. Cancer Res. 63, 8563–8572 (2003).
   PubMed Web of Science ®Google Scholar
• Badie B, Drazan KE, Kramar MH, Shaked A, Black KL. Adenovirus-mediated p53 gene delivery inhibits 9L glioma growth in rats. Neurol. Res. 17, 209–216 (1995).
   PubMed Web of Science ®Google Scholar
• Gomez-Manzano CX, Fueyo J, Kyritsis AP et al. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res. 56, 694–699 (1996).
   PubMed Web of Science ®Google Scholar
• Vecil GG, Lang FF. Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 oncolytic adenoviruses. J. Neuro-oncol. 65, 237–246 (2003).
   PubMed Web of Science ®Google Scholar
• Lang FF, Bruner JM, Fuller GN et al. Phase I trial of adenovirus mediated p53 gene therapy for recurrent glioma: biological and clinical results. J. Clin. Oncol. 21, 2508–2518 (2003).
   PubMed Web of Science ®Google Scholar
• Shinoura N, Saito K, Yoshida Y et al. Adenovirus-mediated transfer of Bax with caspase-8 controlled by myelin basic protein promoter exerts an enhanced cytotoxic effect in gliomas. Cancer Gene Ther. 7, 739–748 (2000).
   PubMed Web of Science ®Google Scholar
• Arafat WO, Buchsbaum DJ, Gómex-Navarro J et al. An adenovirus encoding proapoptotic Bax synergistically radiosensitizes malignant glioma. Int. J. Radiat. Oncol. Biol. Phys. 55, 1037–1050 (2003).
   PubMed Web of Science ®Google Scholar
• Naumann U, Waltereit R, Schulz JB, Weller M. Adenoviral (full-length) APO2L/TRAIL gene transfer is an ineffective treatment strategy for malignant glioma. J. Neuro-oncol. 61, 7–15 (2003).
   PubMed Web of Science ®Google Scholar
• Younes A, Kadin ME. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J. Clin. Oncol. 21, 3526–3534 (2003).
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Pai RC, Fong S et al. Safety and antitumor activity of recombinant soluble APO2 ligand. J. Clin. Invest. 104, 155–162 (1999).
   PubMed Web of Science ®Google Scholar
• Nagane M, Pan G, Weddle JJ et al. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res. 60, 847–853 (2000).
   PubMed Web of Science ®Google Scholar
• Röhn TA, Wagenknecht B, Roth W et al. CCNU-dependent potentiation of TRAIL/APO2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. Oncogene 20, 4128–4137 (2001).
   PubMed Web of Science ®Google Scholar
• Pedersen IM, Kitada S, Schimmer A et al. The triterpenoid CDDO induces apoptosis in refractory CLL B-cells. Blood 100, 2965–2972 (2002).
   PubMed Web of Science ®Google Scholar
• Lu W, Chen L, Peng Y, Chen J. Activation of p53 by roscovitine-mediated suppression of mdm2 expression. Oncogene 20, 3206–3216 (2001).
   PubMed Web of Science ®Google Scholar
• Kim EH, Kim SU, Shin DY, Choi KS. Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene 23, 446–456 (2004).
   PubMed Web of Science ®Google Scholar
• Katoh M, Wilmotte R, Belkouch MC, de Tribolet N, Pizzolato G, Dietrich PY. Survivin in brain tumors: an attractive target for immunotherapy. J. Neuro-oncol. 64, 71–76 (2003).
   PubMed Web of Science ®Google Scholar
• Marte BM, Downward J. PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem. Sci. 22, 355–358 (1997).
   PubMed Web of Science ®Google Scholar
• Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel aklylphospholipid, inhibits protein kinase B. Mol. Cancer Ther. 2, 1093–1103 (2003).
   PubMed Web of Science ®Google Scholar
• Stewart CL, Soria AM, Hamel PA. Integration of the pRb and p53 cell cycle control pathways. J. Neuro-oncol. 51, 183–204 (2001).
   PubMed Web of Science ®Google Scholar
• Sherr CJ. Cancer cell cycles. Science 274, 1672–1677 (1996).
   PubMed Web of Science ®Google Scholar
• Dicks PB, Rutka JT. Current concepts in neuro-oncology: the cell cycle – a review. Neurosurgery 40, 1000–1015 (1997).
   PubMed Web of Science ®Google Scholar
• Poon RYC. Cell cycle control. In: Encyclopedia of Cancer. Volume I. Bertino JR (Ed.), Academic Press, CA, USA, 246–255 (1997).
   Google Scholar
• Clurman BE, Roberts JM. Cell cycle control: an overview. In: The Genetic Basis of Human Cancer. Vogelstein B, Kinzler KW (Eds.), McGraw-Hill, NY, USA, 8, 175–191 (1998).
   Google Scholar
• Ivanchuk SM, Rutka JT. The cell cycle: accelerators, brakes, and checkpoints. Neurosurgery 54, 692–700 (2004).
   PubMed Web of Science ®Google Scholar
• Weinstein IB, Zhou P. Cell cycle control gene defects and human cancer. In: Encyclopedia of Cancer. Volume I. Bertino JR (Ed.), Academic Press, CA, USA, 256–267 (1997).
   Google Scholar
• Zetterberg A, Larsson O, Wiman K. What is the restriction point? Curr. Opin. Cell Biol. 7, 835 (1995).
   PubMed Web of Science ®Google Scholar
• Murray A. Creative blocks: cell-cycle checkpoints and feedback controls. Nature 359, 599–604 (1992).
   PubMed Web of Science ®Google Scholar
• Pines J. Cyclins and cyclin-dependent kinases: a biochemical view. Biochem. J. 308, 697–711 (1995).
   PubMed Web of Science ®Google Scholar
• Sherr CJ. Mammalian G1 cyclins. Cell 73, 1059–1065 (1993).
   PubMed Web of Science ®Google Scholar
• Nigg EA. Cyclin-dependent protein kinases: key regulators of the cell cycle. Bioessays 17, 471–480 (1995).
   PubMed Web of Science ®Google Scholar
• Morgan DO. Principles of Cdk regulation. Nature 374, 131–134 (1995).
   PubMed Web of Science ®Google Scholar
• Jeffrey PD, Russo AA, Polyak K et al. Crystal structure of a cyclin A–Cdk2 complex at 2.3A: mechanism of Cdk activation by cyclins. Nature 376, 313–320 (1995).
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Kato J, Quell D, Matsuoka M, Roussel M. D-type cyclins and their cyclin-dependent kinases: G1 phase integrators of the mitogenic response. Cold Spring Harbor Symp. Quant. Biol. 49, 11–19 (1994).
   Google Scholar
• Quelle DE, Ashmun RA, Shurtleff SA et al. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev. 7, 1559–1571 (1993).
   PubMed Web of Science ®Google Scholar
• De Bondt HL, Rosenblatt J, Jancarik J, Jones HD, Morgan DO, Kim SH. Crystal structure of cyclin-dependent kinase 2. Nature 363, 595–602 (1993).
   PubMed Web of Science ®Google Scholar
• Fisher RP, Morgan DO. A novel cyclin associates with MO15/Cdk7 to form the Cdk-activating kinase. Cell 78, 713–724 (1994).
   PubMed Web of Science ®Google Scholar
• Krek W, Nigg EA. Differential phosphorylation of vertebrate p34Cdc2 kinase at the G1/S and G2/M transitions of the cell cycle: identification of major phosphorylation site. EMBO J. 10, 305–316 (1991).
   PubMed Web of Science ®Google Scholar
• McGowan CH, Russell P. Human Wee1 kinase inhibits cell division by phosphorylating p34Cdc2 exclusively on Tyr15. EMBO J. 12, 75–85 (1993).
   PubMed Web of Science ®Google Scholar
• Dunphy WG. The decision to enter mitosis. Trends Cell Biol. 4, 202–207 (1994).
   PubMedGoogle Scholar
• Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805–816 (1993).
   PubMed Web of Science ®Google Scholar
• El-Deiry WS, Tokino T, Velculescu VE et al. Waf1, a potential mediator of p53 tumor suppression. Cell 75, 817–825 (1993).
   PubMed Web of Science ®Google Scholar
• Peter M, Herskowitz I. Joining the complex: cyclin dependent kinase inhibitory proteins and cell cycle. Cell 79, 181–184 (1994).
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Roberts J. Inhibitors of mammalian G1 cyclin-dependent kinases. Gene Dev. 9, 1149–1163 (1995).
   PubMed Web of Science ®Google Scholar
• Nigg EA. Targets of cyclin-dependent protein kinases. Curr. Opin. Cell Biol. 5, 187–193 (1993).
   PubMed Web of Science ®Google Scholar
• Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 81, 323–330 (1995).
   PubMed Web of Science ®Google Scholar
• Moran E. DNA tumor virus transforming proteins and the cell cycle. Curr. Opin. Genet. Dev. 3, 63–70 (1993).
   PubMed Web of Science ®Google Scholar
• Lees JA, Saito M, Vidal M et al. The retinoblastoma protein binds to a family of E2F transcription factors. Mol. Cell Biol. 13, 7813–7825 (1993).
   PubMed Web of Science ®Google Scholar
• Wu CL, Zukerberg LR, Ngwu C, Harlow E, Lees JA. In vivo association of E2F and DP family proteins. Mol. Cell Biol. 15, 2536–2546 (1995).
   PubMed Web of Science ®Google Scholar
• Lees JA, Buchkovich KJ, Marshak DR, Anderson CW, Harlow E. The retinoblastoma protein is phosphorylated on multiple sites by human Cdc2. EMBO J. 10, 4279–4290 (1991).
   PubMed Web of Science ®Google Scholar
• Dyson N. pRb, p107, and the regulation of the E2F transcription factor. J. Cell Sci. Suppl. 18, 81–87 (1994).
   PubMedGoogle Scholar
• Krek W, Ewen M, Shirodkar S, Arany Z, Kaelin W, Livingston D. Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase. Cell 78, 161–172 (1994).
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Roberts JM. Cdk inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13, 1501–1512 (1999).
   PubMed Web of Science ®Google Scholar
• Peters JM. The anaphase-promoting complex: proteolysis in mitosis and beyond. Mol. Cell 9, 931–943 (2002).
   PubMed Web of Science ®Google Scholar
• Pfleger CM, Lee E, Kirschner MW. Substrate recognition by the Cdc20 and Cdh1 components of the anaphase-promoting complex. Genes Dev. 15, 2396–2407 (2002).
   Web of Science ®Google Scholar
• Gieffers C, Peters BH, Kramer ER, Dotti CG, Peters JM. Expression of the Cdh1-associated form of the anaphase-promoting complex in postmitotic neurons. Proc. Natl Acad. Sci. USA 96, 11317–11322 (1999).
   PubMed Web of Science ®Google Scholar
• Roos-Mattjus, Sistonen L. The ubiquitin-proteasome pathway. Ann. Med. 36, 285–295 (2004).
   PubMed Web of Science ®Google Scholar
• Rechsteiner MC. Ubiquitin-mediated proteolysis: an ideal pathway for systems biology analysis. Adv. Exp. Med. Biol. 547, 49–59 (2004).
   PubMed Web of Science ®Google Scholar
• Zackon IL, Goolsby CL. A clinician’s guide to flow cytometry. Contemp. Oncol. 4, 14–36 (1994).
   Google Scholar
• Christov K, Zapryanov Z. Flow cytometry in brain tumors. I. Ploidy abnormalities. Neoplasma 33, 49–55 (1986).
   PubMed Web of Science ®Google Scholar
• Giangaspero F, Chieco P, Lisignoli G, Burger PC. Comparison of cytologic composition with microfluorometric DNA analysis of the glioblastoma multiforme and anaplastic astrocytoma. Cancer 60, 59–65 (1987).
   PubMed Web of Science ®Google Scholar
• Zaprianov Z, Christov K. Histological grading, DNA content, cell proliferation and survival of patients with astroglial tumors. Cytometry 9, 380–386 (1988).
   PubMedGoogle Scholar
• Tomita T, Yasue M, Engelhard HH, McLone DG, Gonzalez-Crussi F, Bauer KD. Flow cytometric DNA analysis of medulloblastoma. Prognostic implication of aneuploidy. Cancer 61, 744–749 (1988).
   PubMed Web of Science ®Google Scholar
• Kros JM, van Eden CG, Vissers CJ, Mulder AH, van der Kwast TH. Prognostic relevance of DNA flow cytometry in oligodendroglioma. Cancer 69, 1791–1798 (1992).
   PubMed Web of Science ®Google Scholar
• Salmon I, Kiss R, Dewitte O et al. Histopathologic grading and DNA ploidy in relation to survival among 206 adult astrocytic tumor patients. Cancer 70, 538–546 (1992).
   PubMed Web of Science ®Google Scholar
• Biernat W, Tohma Y, Yonekawa Y, Kleihues P, Ohgaki H. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol. 94, 303–309 (1997).
   PubMed Web of Science ®Google Scholar
• Yin D, Xie D, Hofmann WK, Miller CW, Black KL, Koeffler HP. Methylation, expression, and mutation analysis of the cell cycle control genes in human brain tumors. Oncogene 21, 8372–8378 (2002).
   PubMed Web of Science ®Google Scholar
• He J, Allen JR, Collins VP. Cdk4 amplification is an alternative mechanism to p16 homozygous deletion in glioma cell lines. Cancer Res. 54, 5804–5807 (1994).
   PubMed Web of Science ®Google Scholar
• He J, Olson JJ, James CD. Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of Cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res. 55, 4833–4836 (1995).
   PubMed Web of Science ®Google Scholar
• Chakrabarty A, Bridges LR, Gray S. Cyclin D1 in astrocytic tumours: an immunohistochemical study. Neuropathol. Appl. Neurobiol. 22, 311–316 (1996).
   PubMed Web of Science ®Google Scholar
• Costello JF, Plass C, Arap W et al. Cyclin-dependent kinase 6 (Cdk6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res. 57, 1250–1254 (1997).
   PubMed Web of Science ®Google Scholar
• Dirks PB, Hubbard SL, Murakami M, Rutka JT. Cyclin and cyclin-dependent kinase expression in human astrocytoma cell lines. J. Neuropathol. Exp. Neurol. 56, 291–300 (1997).
   PubMed Web of Science ®Google Scholar
• Chakrabarty A, Bridges LR. Immunohistochemical analysis of cyclin A in astrocytic tumours. J. Neuropathol. Appl. Neurobiol. 24, 239–245 (1998).
   PubMed Web of Science ®Google Scholar
• Machen SK, Prayson RA. Cyclin D1 and MIB-1 immunochemistry in pilocytic astrocytomas: a study of 48 cases. Hum. Pathol. 29, 1511–1516 (1998).
   PubMed Web of Science ®Google Scholar
• Kamiya M, Nakazato Y. The expression of cell cycle regulatory proteins in oligodendroglial tumors. Clin. Neuropathol. 21, 52–65 (2002).
   PubMed Web of Science ®Google Scholar
• Giani C, Finocchiaro G. Mutation rate of CdkN2 gene in malignant glioma. Cancer Res. 54, 6338–6339 (1994).
   PubMed Web of Science ®Google Scholar
• Jen J, Harper JW, Bigner SH et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res. 54, 6353–6358 (1994).
   PubMed Web of Science ®Google Scholar
• Nishikawa R, Furnari FB, Lin H et al. Loss of p16INK4 expression is frequent in high grade gliomas. Cancer Res. 55, 1941–1945 (1995).
   PubMed Web of Science ®Google Scholar
• Ono Y, Tamiya T, Ichikawa T et al. Malignant astrocytomas with homozygous CdkN2/p16 gene deletions have higher Ki-67 proliferation indices. J. Neuropathol. Exp. Neurol. 55, 1026–1031 (1996).
   PubMed Web of Science ®Google Scholar
• Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN. CdkN2/p16 or Rb alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res. 56, 150–153 (1996).
   PubMed Web of Science ®Google Scholar
• Miettinen H, Kononen J, Sallinen P et al. CdkN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas. J. Neuro-oncol. 41, 205–211 (1999).
   PubMed Web of Science ®Google Scholar
• Kirla R, Salminen E, Huhtala S et al. Prognostic value of the expression of tumor suppressor genes p53, p21, p16 and pRb, and Ki-67 labelling in high grade astrocytomas treated with radiotherapy. J. Neuro-oncol. 46, 71–80 (2000).
   PubMed Web of Science ®Google Scholar
• Kirla RM, Haapasalo HK, Kalimo H, Salminen EK. Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas. Cancer 97, 644–648 (2001).
   Web of Science ®Google Scholar
• Kamiryo T, Tada K, Shiraishi S et al. Analysis of homozygous deletion of the p16 gene and correlation with survival in patients with glioblastoma multiforme. J. Neurosurg. 96, 815–822 (2002).
   PubMed Web of Science ®Google Scholar
• Costello JF, Berger MS, Huang HJ, Cavanee WK. Silencing of p16/CdkN2 expression in human gliomas by methylation and chromosome condensation. Cancer Res. 56, 2405–2410 (1996).
   PubMed Web of Science ®Google Scholar
• Herman JG, Jen J, Merlo A, Baylin SB. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res. 56, 722–727 (1996).
   PubMed Web of Science ®Google Scholar
• Venter DJ, Bevan KL, Ludwig RL et al. Retinoblastoma gene deletions in human glioblastomas. Oncogene 6, 445–448 (1991).
   PubMed Web of Science ®Google Scholar
• Henson JW, Schnitker BL, Correa KM et al. The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann. Neurol. 36, 714–721 (1994).
   PubMed Web of Science ®Google Scholar
• McNeish IA, Bell SJ, Lemoine NR. Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes. Gene Ther. 11, 497–503 (2004).
   PubMed Web of Science ®Google Scholar
• Fueyo J, Gomez-Manzano C, Liu TJ, Yung WKA. Delivery of cell cycle genes to block astrocytoma growth. J. Neuro-oncol. 51, 277–287 (2001).
   PubMed Web of Science ®Google Scholar
• Fueyo J, Gomex-Manzano C, Yung WKA et al. Suppression of human glioma growth by adenovirus-mediated Rb gene transfer. Neurology 50, 1307–1315 (1998).
   PubMed Web of Science ®Google Scholar
• Fueyo J, Alemany R, Gomez-Manzano C et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J. Natl Cancer Inst. 95, 652–660 (2003).
   PubMed Web of Science ®Google Scholar
• Arap W, Nishikawa, Furnari FB, Cavanee WK, Huang HSS. Replacement of the p16/CdkN2 gene suppresses human glioma cell growth. Cancer Res. 55, 1351–1354 (1995).
   PubMed Web of Science ®Google Scholar
• Fueyo J, Gomez-Manzano C, Yung WKA et al. Adenovirus-mediated p16/CdkN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene 12, 103–110 (1996).
   PubMed Web of Science ®Google Scholar
• Chintala SK, Fueyo J, Gomez-Manzano C et al. Adenovirus-mediated p16/CdkN2 gene transfer suppresses glioma invasion in vitro. Oncogene 15, 2049–2057 (1997).
   PubMed Web of Science ®Google Scholar
• Harada H, Nakagawa K, Iwata S et al. Restoration of wild type p16 downregulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res. 59, 3783–3789 (1999).
   PubMed Web of Science ®Google Scholar
• Hung KS, Hong CY, Lee J et al. Expression of p16INK4A induces dominant suppression of glioblastoma growth in situ through necrosis and cell cycle arrest. Biochem. Biophys. Res. Commun. 269, 718–725 (2000).
   PubMed Web of Science ®Google Scholar
• Simon M, Christian S, Köster G, Hans VHJ, Schramm J. Conditional expression of the tumor suppressor p16 in a heterotopic glioblastoma model results in loss of pRb expression. J. Neuro-oncol. 60, 1–12 (2002).
   PubMed Web of Science ®Google Scholar
• Komata T, Kanzawa T, Takeuchi H et al. Antitumor effect of cyclin-dependent kinase inhibitors (p16INK4A, p18INK4C, p19INK4D, p21Waf1/Cip1 and p27Kip1) on malignant glioma cells. Br. J. Cancer 88, 1277–1280 (2003).
   PubMed Web of Science ®Google Scholar
• Fueyo J, Gomez-Manzano C, Yung WKA et al. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nature Med. 4, 685–690 (1998).
   PubMed Web of Science ®Google Scholar
• Kamb A. Cyclin-dependent kinase inhibitors and human cancer. Curr. Top. Microbiol. Immunol. 227, 139–148 (1998).
   PubMed Web of Science ®Google Scholar
• Shapiro GI, Harper JW. Anticancer drug targets: cell cycle and checkpoint control. J. Clin. Invest. 104, 1645–1653 (1999).
   PubMed Web of Science ®Google Scholar
• Garrett MD, Fattaey A. Cdk inhibition and cancer therapy. Curr. Opin. Genet. Dev. 9, 104–111 (1999).
   PubMed Web of Science ®Google Scholar
• McDonald ER, El Deiry WS. Cell cycle control as a basis for cancer drug development. Int. J. Oncol. 16, 871–886 (2000).
   PubMed Web of Science ®Google Scholar
• Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl Cancer Inst. 92, 376–387 (2000).
   PubMed Web of Science ®Google Scholar
• Sausville EA. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol. Med. 8, S32–S37 (2002).
   PubMed Web of Science ®Google Scholar
• Dai Y, Grant S. Cyclin-dependent kinase inhibitors. Curr. Opin. Pharmacol. 3, 362–370 (2003).
   PubMed Web of Science ®Google Scholar
• Sausville EA. Cyclin-dependent kinase modulators studied at the NCI: preclinical and clinical studies. Anticancer Agents Curr. Med. Chem. 3, 47–56 (2003).
   PubMedGoogle Scholar
• Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 36, 131–149 (2003).
   PubMed Web of Science ®Google Scholar
• Kubo A, Kaye FJ. Searching for selective cyclin-dependent kinase inhibitors to target the retinoblastoma/p16 cancer gene pathway. J. Natl Cancer Inst. 93, 415–417 (2001).
   PubMedGoogle Scholar
• Fahraeus R, Paramio JM, Ball KL, Lain S, Lane DP. Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CdkN2/INK4A. Curr. Biol. 6, 84–91 (1996).
   PubMed Web of Science ®Google Scholar
• Chen YN, Sharma SK, Ramsey TM et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc. Natl Acad. Sci. USA 96, 4325–4329 (1999).
   PubMed Web of Science ®Google Scholar
• Adams J, Palombella VJ, Sausville EA et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59, 2615–2622 (1999).
   PubMed Web of Science ®Google Scholar
• Adams J, Palombela VJ, Elliott PJ. Proteasome inhibition: a new strategy in cancer treatment. Invest. New Drugs 18, 109–121 (2000).
   PubMed Web of Science ®Google Scholar
• Adams J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol. Med. 8, S49–S54 (2002).
   PubMedGoogle Scholar
• Lenz HJ. Clinical update: proteasome inhibitors in solid tumors. Cancer Treat. Rev. 29, 41–48 (2003).
   PubMed Web of Science ®Google Scholar
• Park DJ, Lenz HJ. The role of proteasome inhibitors in solid tumors. Ann. Med. 36, 296–303 (2004).
   PubMed Web of Science ®Google Scholar
• Piva R, Cancelli I, Cavalla P et al. Proteasome-dependent degradation of p27/Kip1 in gliomas. J. Neuropathol. Exp. Neurol. 58, 691–696 (1999).
   PubMed Web of Science ®Google Scholar
• Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res. 5, 2638–2645 (1999).
   PubMed Web of Science ®Google Scholar
• Adams J. Development of the proteasome inhibitor PS-341. Oncologist 7, 9–16 (2002).
   PubMed Web of Science ®Google Scholar
• Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 22, 304–311 (2004).
   PubMed Web of Science ®Google Scholar
• Kitigawa H, Tani E, Ikemoto H, Ozaki I, Nakano A, Omura S. Proteasome inhibitors induce mitochondria-independent apoptosis in human glioma cells. FEBS Lett. 443, 181–186 (1999).
   PubMed Web of Science ®Google Scholar
• Wagenknecht B, Hermisson M, Groscurth P, Liston P, Krammer PH, Weller M. Proteasome inhibitor-induced aoptosis of glioma cells involves the processing of multiple caspases and cytochrome release. J. Neurochem. 75, 2288–2297 (2000).
   PubMed Web of Science ®Google Scholar
• Laurent N, de Bouard S, Guillamo JS et al. Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo. Mol. Cancer Ther. 3, 129–136 (2004).
   PubMed Web of Science ®Google Scholar
• Newcomb EW. Flavopiridol: pleiotropic biological effects enhance its anticancer activity. Anticancer Drugs 15, 411–419 (2004).
   PubMed Web of Science ®Google Scholar
• Alonso M, Tamasdan C, Miller DC, Newcomb EW. Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway. Mol. Cancer Ther. 2, 139–150 (2003).
   PubMed Web of Science ®Google Scholar
• Newcomb EW, Tamasdan C, Entzminger Y et al. Flavopiridol induces mitochondrial-mediated apoptosis in murine glioma GL261 cells via release of cytochrome c and apoptosis inducing factor. Cell Cycle 2, 243–250 (2003).
   PubMed Web of Science ®Google Scholar
• Newcomb EW, Tamasdan C, Entzminger Y et al. Flavopiridol inhibits the growth of GL261 gliomas in vivo: implications for malignant glioma therapy. Cell Cycle 3, 230–234 (2004).
   PubMed Web of Science ®Google Scholar
• Senderowicz AM, Headlee D, Stinson SF et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncol. 16, 2986–2999 (1998).
   PubMed Web of Science ®Google Scholar
• Schwartz GK, O’Reilly E, Ilson D et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J. Clin. Oncol. 20, 2157–2170 (2002).
   PubMed Web of Science ®Google Scholar
• Burdette-Radoux S, Tozer RG, Lohmann RC et al. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic melanoma. Invest. New Drugs 22, 315–322 (2004).
   PubMed Web of Science ®Google Scholar
• Pollack IF, Kawecki S, Lazo JS. Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor. J. Neurosurg. 84, 1024–1032 (1996).
   PubMed Web of Science ®Google Scholar
• Bredel M, Pollack IF, Freund JM, Rusnak J, Lazo JS. Protein kinase C inhibition by UCN-01 induces apoptosis in human glioma cells in a time-dependent fashion. J. Neuro-oncol. 41, 9–20 (1999).
   PubMed Web of Science ®Google Scholar
• Meijer L, Borgne A, Mulner O et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases Cdc2, Cdk2 and Cdk5. Eur. J. Biochem. 243, 527–536 (1997).
   PubMedGoogle Scholar
• Whittaker SR, Walton MI, Garrett MD, Workman P. The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res. 64, 262–272 (2004).
   PubMed Web of Science ®Google Scholar
• Yakisich JS, Boethius J, Lindblom IO et al. Inhibition of DNA synthesis in human gliomas by roscovitine. Neuroreport 10, 2563–2567 (1999).
   PubMed Web of Science ®Google Scholar
• Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, Sarkaria JN. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res. 62, 7291–7297 (2002).
   PubMed Web of Science ®Google Scholar
• Garrett MD, Workman P. Discovering novel chemotherapeutic drugs for the third millennium. Eur. J. Cancer 35, 2010–2030 (1999).
   PubMed Web of Science ®Google Scholar
• Gelman KA, Eisenhauer EA, Harris AL, Ratain MJ, Workman P. Anticancer agents targeting signaling molecules and cancer cell environments: challenges for drug development? J. Natl Cancer Inst. 91, 1281–1287 (1999).
   PubMedGoogle Scholar
• Clarke PA, te Poele R, Wooster R, Workman P. Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential. Biochem. Pharmacol. 62, 1311–1336 (2001).
   PubMed Web of Science ®Google Scholar
• Workman P. The impact of genomic and proteomic technologies on the development of new cancer drugs. Ann. Oncol. 13, 115–124 (2002).
   PubMed Web of Science ®Google Scholar
• Groothuis DR. The blood–brain and blood–tumor barriers: a review of strategies for increasing drug delivery. J. Neuro-oncol. 1, 45–59 (2000).
   Google Scholar
• Degen JW, Walbridge S, Vortmeyer AO, Oldfield EH, Lonser RR. Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats. J. Neurosurg. 99, 893–898 (2003).
   PubMed Web of Science ®Google Scholar
• Lidar Z, Mardor Y, Jonas T et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a Phase I/II clinical trial. J. Neurosurg. 100, 472–479 (2004).
   PubMed Web of Science ®Google Scholar
• Scheck AC. Molecular biology of chemotherapy and resistance. BNI Q 14, 43–54 (1998).
   Google Scholar
• Clarke PA, te Poele R, Wooster R, Workman P. Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential. Biochem. Pharmacol. 62, 1311–1336 (2001).
   PubMed Web of Science ®Google Scholar
• Ramaswamy S, Golub TR. DNA microarrays in clinical oncology. J. Clin. Oncol. 20, 1932–1941 (2001).
   Web of Science ®Google Scholar
• Mohr S, Leikauf GD, Keith G, Rihn BH. Microarrays as cancer keys: an array of possibilities. J. Clin. Oncol. 20, 3165–3175 (2002).
   PubMed Web of Science ®Google Scholar
• Sturla LM, Fernandez-Teijeiro A, Pomeroy SL. Application of microarrays to neurological disease. Arch. Neurol. 60, 676–682 (2003).
   PubMedGoogle Scholar